Similarly, in contrast to uniform CD19 expression, we observed heterogeneity in both percentage and density of CD20 and CD22 in a cohort of 12 patients with BL-ALL who relapsed after chemotherapy (Fig. 1b). The gene discussed is CD22; the disease is Burkitt lymphoma.